The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance
Open accessAbstract
Background: Differential expression of mucins has been associated with several cancers including colorectal cancer (CRC). In normal physiological conditions, secretory mucin MUC5AC is not expressed in the colonic mucosa, whereas its aberrant expression is observed during development of colon cancer and its precursor lesions. To date, the molecular mechanism of MUC5AC in CRC progression and drug resistance remains obscure. Methods: MUC5AC expression was determined in colon tissue microarray by immunohistochemistry. A RNA interference and CRISPR/Cas9-mediated system was used to knockdown/knockout the MUC5AC in CRC cell lines to delineate its role in CRC tumorigenesis using in vitro functional assays and in vivo (sub-cutaneous and colon orthotopic) mouse models. Finally, CRC cell lines and xenograft models were used to identify the mechanism of action of MUC5AC. Results: Overexpression of MUC5AC is observed in CRC patient tissues and cell lines. MUC5AC expression resulted in enhanced cell invasion and migration, and decreased apoptosis of CRC cells. MUC5AC interacted with CD44 physically, which was accompanied by the activation of Src signaling. Further, the presence of MUC5AC resulted in enhanced tumorigenesis and appearance of metastatic lesions in orthotopic mouse model. Additionally, up-regulation of MUC5AC resulted in resistance to 5-fluorouracil (5-FU) and oxaliplatin, and its knockout increased sensitivity to these drugs. Finally, we observed that up-regulation of MUC5AC conferred resistance to 5-FU through down-regulation of p53 and its target gene p21 and up-regulation of β-catenin and its target genes CD44 and Lgr5. Conclusion: Our findings suggest that differential expression of secretory mucin MUC5AC results in enhanced tumorigenesis and also confers chemoresistance via CD44/β-catenin/p53/p21 signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
MicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer
Zhang, Y., Geng, L., Talmon, G., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620252 · Cited by 100
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
CD44: A Multifunctional Mediator of Cancer Progression
Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021) · Biomolecules · doi:10.3390/biom11121850 · Cited by 492
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
Metadata
- Authors
- Pothuraju, R., Rachagani, S., Krishn, S. R., Chaudhary, S., Nimmakayala, R. K., Siddiqui, J. A., Ganguly, K., Lakshmanan, I., Cox, J. L., Mallya, K., Kaur, S., & Batra, S. K.
- Venue
- Molecular Cancer
- Published
- 2020-02-25
- Volume
- 19
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W3009560356
- Cited by
- 160
- References
- 2
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. https://app.cochat.ai/papers/10.1186/s12943-020-01156-y
- The paper
- Pothuraju, R., Rachagani, S., Krishn, S. R., Chaudhary, S., Nimmakayala, R. K., Siddiqui, J. A., Ganguly, K., Lakshmanan, I., Cox, J. L., Mallya, K., Kaur, S., & Batra, S. K. (2020). Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Molecular Cancer. https://doi.org/10.1186/s12943-020-01156-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.